Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 42: 1634-1638, 1996;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dittadi, R.
Right arrow Articles by Gianneo, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dittadi, R.
Right arrow Articles by Gianneo, E.

Clinical Chemistry, Vol 42, 1634-1638, Copyright © 1996 by American Association for Clinical Chemistry

Standardization of assay for cytokeratin-related tumor marker CYFRA21.1 in urine samples

R Dittadi, P Barioli, M Gion, R Mione, M Barichello, G Capitanio, G Cocco, G Cazzolato, F De Biasi, S Praturlon, R Antinozzi and E Gianneo
Centro Regionale per lo Studio degli Indicatori Biochimici di Tumore e Centro Nazionale per L'Applicazione delle Biotecnologie in Oncologia, Ospedale Civile, Venezia, Italy.

The determination of tumor markers in urine samples has been proposed as an effective diagnostic tool in bladder cancer. The aim of the present investigation was to validate in urine samples the assay of the CYFRA21.1 cytokeratin-related marker, the serum concentrations of which showed promising diagnostic utility in patients with bladder cancer. First-voided urine samples were collected from patients with different malignancies. CYFRA21.1 was assayed with a commercially available enzyme immunoassay (Boehringer Mannheim). Different centrifugation patterns, the use of different buffers and nonionic detergents, and pH variations were evaluated. We demonstrated that: (a) cells and cell debris contain a large amount of CYFRA21.1 and must be eliminated by centrifugation; (b) storage at -20 degrees C causes amorphous precipitate, which may aspecifically bind CYFRA21.1; (c) the latter behavior may be prevented by diluting fresh urine samples with phosphate buffer with nonionic detergent added; (d) pH variations within the range 4.9-8.2 do not significantly affect CYFRA21.1 assay results. Provided that samples are diluted with buffer containing nonionic detergent, the CYFRA21.1 assay showed good precision and accuracy characteristic in urine samples. We therefore propose a standard protocol for the collection of urine samples for CYFRA21.1 assay. In a preliminary clinical evaluation, CYFRA21.1 concentrations in 16 patients with primary bladder cancer were higher than in healthy subjects. In the urine collected in the follow-up of patients treated for bladder cancer, CYFRA21.1 tended to be higher in relapsed patients than in those without evidence of disease. These preliminary data induced us to extend the clinical trial to establish the actual role of this assay in routine use.


The following articles in journals at HighWire Press have cited this article:


Home page
 Am. J. Physiol. Renal Physiol.Home page
P. Saetun, T. Semangoen, and V. Thongboonkerd
Characterizations of urinary sediments precipitated after freezing and their effects on urinary protein and chemical analyses
Am J Physiol Renal Physiol, June 1, 2009; 296(6): F1346 - F1354.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Sánchez-Carbayo, M. Urrutia, J. M. G. de Buitrago, and J. A. Navajo
Evaluation of Two New Urinary Tumor Markers: Bladder Tumor Fibronectin and Cytokeratin 18 for the Diagnosis of Bladder Cancer
Clin. Cancer Res., September 1, 2000; 6(9): 3585 - 3594.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
M. Sanchez-Carbayo, A. Espasa, V. Chinchilla, E. Herrero, J. Megias, A. Mira, and F. Soria
New Electrochemiluminescent Immunoassay for the Determination of CYFRA 21-1: Analytical Evaluation and Clinical Diagnostic Performance in Urine Samples of Patients with Bladder Cancer
Clin. Chem., November 1, 1999; 45(11): 1944 - 1953.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Association for Clinical Chemistry.